Tuesday, February 11, 2025
HomeStart UpNeuranics raises $700K in seed funding to transform blood diagnostics

Neuranics raises $700K in seed funding to transform blood diagnostics

Neuranics, a healthcare diagnostics startup, recently raised USD 700K in a seed funding round led by Inflection Point Ventures (IPV). The startup plans to use the funds to enhance its technology and validate clinical applications. This funding will help Neuranics achieve its mission to transform blood diagnostics and speed up healthcare solutions.

The company is building a cutting-edge point-of-care blood analyzer that delivers complete blood count (CBC) results in under 10 minutes. The device requires just a finger-prick sample and is ideal for primary and emergency healthcare settings. Its low-maintenance design and high efficiency make it a revolutionary tool for the healthcare industry.

Providing immediate CBC results directly to physicians enables quicker and more informed decisions on patient care. This eliminates delays caused by transporting and processing clinical samples. Physicians benefit from the confidence to diagnose and treat conditions promptly. Patients experience improved outcomes, while the healthcare system saves costs by avoiding unnecessary treatments like inappropriate antibiotics. Additionally, life-saving interventions for conditions like sepsis, anemia, and thrombocytopenia can begin without delay, especially for critical cases like dengue patients.

Neuranics’ innovative design integrates compact, dry hematology technology with unmatched efficiency, allowing it to meet the growing demand for accurate and fast diagnostics.

Founded in 2021 by Praveen Kumar (CEO) and Ashutosh Patra (CTO), Neuranics addresses key gaps in diagnostic technology. Praveen, an IIT Delhi graduate, has extensive experience in healthcare tech and has worked on government initiatives like Corona Kavach and Aarogya Setu. Ashutosh, an alumnus of the SiB program at AIIMS, drives product innovation with expertise in optical sensing and mechanical engineering. Together, they’ve achieved milestones such as securing a patent, obtaining the CDSCO Test License, and receiving ethical approvals from AIIMS Delhi. The team is currently advancing through clinical trials.

Mitesh Shah, Co-founder of IPV, says, “Neuranics is tackling the problem of lengthy and complex blood testing processes with their point-of-care blood analyzer that makes complete blood count diagnosis faster and easier. This significantly improves patient care, especially in urgent cases. IPV believes in the startups innovative technology and envisions a future where the startups bring out more such necessary tools”.

Dr Megha Sharma, MD Pathologist and Chief Medical Evangelist at Neuranics, says, “Our point-of-care CBC analyzer represents a significant leap forward in diagnostic convenience and accessibility. By utilizing a simple finger-prick capillary blood sample. We have effectively eliminated the need for traditional venipuncture, making blood testing faster, less invasive, and more patient-friendly. This technology empowers healthcare providers to deliver immediate, actionable insights, even in resource-limited settings, ultimately improving patient outcomes especially in Primary health care centres for screening and at emergency setups for triage. ”

Neuranics has gained recognition through accolades like YourStory Tech30, Amazon-Sambhav, and the India-Sweden Innovation Challenge. These achievements highlight its potential to decentralize routine diagnostics, making tests for anemia, thalassemia, malaria, and leukemia faster and more accessible. 

Praveen Kumar, Co-founder & CEO of Neuranics, says, “We are re-imagining how we approach diagnostics by bringing instant, accurate blood analysis closer to the patient without compromising quality. Our technology empowers clinicians with real-time data, transforming care delivery and elevating patient outcomes.

By leveraging AI on de-identified pathological imaging data generated by our analyzer, we aim to set a new gold standard for national screening programs. This innovative technology will elevate healthcare quality in India and establish the country as a global leader in point of care blood analyser.

We thank IPV for being with us in this journey. Working with IPV has been a streamlined and transformative experience. Their investment and guidance have empowered us to scale faster, innovate further, and bring our vision to life. IPV’s efficient processes and industry connections have been instrumental in our journey.”

In the $50 billion global CBC market, Neuranics is poised to lead the next wave of diagnostic technology. The company is setting new standards in healthcare diagnostics by focusing on precision robotics, machine vision, and microfluidics.

Subscribe To Newsletter

ICYMI

BRL Editor
BRL Editorhttps://businessreviewlive.com
Business Review Live covers finance, technology, travel, lifestyle, and everything in between through exclusive interviews and analysis, market statistics, digital video, and an expanded array of content formats.